Page 180 - 2019秋季手冊內頁-ebook測試

EDUCATIONAL CERTIFICATE:
• 教育部部定講師講字第105938號 • 教育部部定助理教授
PUBLICATIONS:
1. Hsieh YY, Fang WT, Lo YW, Chen YH, Chien LN. Comparing the effectiveness of different EGFR‐TKIs in
patients with EGFR mutant non‐small‐cell lung cancer: A retrospective cohort study in Taiwan. Int J
Cancer. 2019 Dec 19. doi:10.1002/ijc.32841
2. Chen SH, Chow JM, Hsieh YY, Lin CY, Hsu KW, Hsieh WS, Chi WM, Shabangu BM, Lee CH. HDAC1,2
Knock‐Out and HDACi Induced Cell Apoptosis in Imatinib‐Resistant K562 Cells. Int J Mol Sci. 2019 May
8;20(9). pii: E2271.
3. Hsieh YY, Liu TP, Yang PM. In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1‐high
expressing clear cell renal carcinoma. Pathol Res Pract. 2019 Jun;215(6):152373.
4. Liu TP, Hsieh YY, Chou CJ, Yang PM. Systematic polypharmacology and drug repurposing via an integrated L1000‐based Connectivity Map database mining. R Soc Open Sci. 2018 Nov
28;5(11):181321.
5. Yao‐Yu Hsieh, Tsui‐Chin Huang, Hsiang‐Ling Lo, et al. Systematic discovery of drug action mechanisms
by an integrated chemical genomics approach: identification of functional disparities between
azacytidine and decitabine. Oncotarget. 2016;7:27363‐78.
6. Hsieh YY, Lo HL, Yang PM. EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and
cytoprotective unfolded protein response in human colorectal cancer cells. Am J Cancer Res.
2016;6:1661‐80.
7. Hsieh YY, Chou CJ, Lo HL, Yang PM. Repositioning of a cyclin‐dependent kinase inhibitor GW8510 as a
ribonucleotide reductase M2 inhibitor to treat human colorectal cancer. Cell Death Discov.
2016;2:16027.
8. Hsieh YY, Yang ST, Li WH, Hu CJ, Wang LS. Primary Leptomeningeal Melanoma Mimicking Meningitis:
A Case Report and Literature Review. J Clin Oncol. 2015;33:e57‐61.
9. Siu MK, Abou‐Kheir W, Yin JJ, Chang YS, Barrett B, Suau F, Casey O, Chen WY, Fang L, Hynes P, Hsieh
YY, Liu YN, Huang J, Kelly K. Loss of EGFR signaling regulated miR‐203 promotes prostate cancer bone
metastasis and tyrosine kinase inhibitors resistance. Oncotarget. 2014;5:3770‐84
10. Hsieh YY, Tzeng CH, Chen MH, et al. Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild‐type colorectal cancer patients treated with cetuximab‐based
chemotherapy. Cancer Sci. 2012;103:791‐6
11. Hsieh YY, Hong YC, Hsiao LT, et al. Effect of allogeneic haematopoietic stem cell transplantation from
matched siblings or unrelated donors during the first complete remission in patients with
cytogenetically normal acute myeloid leukaemia. Eur J Haematol 2011;86:237‐45
12. Hsieh YY, Liu CJ, Liu CY, et al. Characteristics and risk factors for abscesses in a consecutive cohort of patients with acute myeloid leukemia patients: a tertiary care center experience. Haematologica
2011;96(s2):337
13. Hsieh YY, Liu CJ, Teng TJ, et al. Characteristics and risk factors for deep tissue abscesses in a
consecutive cohort of patients with acute myeloid leukemia: a national population study in Taiwan.
Haematologica 2011;96(s2):639
14. Hsieh YY, Liu CJ, Teng TJ, et al. Cirrhosis associated with poor outcome in acute myeloid leukemia
patients developed liver abscess: a national population study in Taiwan. Haematologica
2011;96(s2):639
15. Liu JH *, Hsieh YY *, Chen WS*, et al. Adjuvant oxaliplatin‐ or irinotecan‐containing chemotherapy
improves overall survival following resection of metachronous colorectal liver metastases. Int J
Colorectal Dis 2010;25:1243‐9 (Co‐first author)
16. Hsieh YY, Chang PM, Chen MH, et al. Pretreatment risk stratification for non‐metastatic head and
neck squamous cell carcinoma in a high‐prevalence area. J Chin Med Assoc 2011;74:487‐92
17. Hsieh YY, Yen CC, Yeh CN, et al. Effective salvage therapy of imatinib‐resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin. J Chin Med Assoc
181